Uveal melanoma (UM) is an intraocular malignancy with poor survival rates due to the propensity for metastatic spread. Although treatment options exist for localized disease, there are fewer definitive guidelines for metastatic UM. Treatment involves a personalized approach that entails patient-specific aspects, including tumor genetics. This case highlights the disease course of a 60-year-old male diagnosed with stage IIB right eye choroidal melanoma. Despite successful therapy for localized UM, he developed widespread metastasis. He received dual immunotherapy and was ultimately maintained on a single-agent regimen. His prognosis has surpassed initial prognosis and survival expectations. This case highlights the use of immunotherapy, both dual and single therapy, to treat this rare malignancy and extend overall survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301674PMC
http://dx.doi.org/10.7759/cureus.26146DOI Listing

Publication Analysis

Top Keywords

uveal melanoma
8
case highlights
8
rare case
4
case metastatic
4
metastatic uveal
4
melanoma responding
4
responding immunotherapy
4
immunotherapy uveal
4
melanoma intraocular
4
intraocular malignancy
4

Similar Publications

Background: Muscle-invasive bladder cancer (MIBC) is a prevalent cancer characterized by molecular and clinical heterogeneity. Assessing the spatial heterogeneity of the MIBC microenvironment is crucial to understand its clinical significance.

Methods: In this study, we used imaging mass cytometry (IMC) to assess the spatial heterogeneity of MIBC microenvironment across 185 regions of interest in 40 tissue samples.

View Article and Find Full Text PDF

Purpose: To investigate the clinical outcomes of stereotactic body radiation therapy (SBRT) in patients with large uveal melanoma (UM).

Materials And Methods: We conducted a retrospective review of 64 consecutive patients with UM treated with Cyberknife at Yonsei Cancer Center from September 2015 to October 2021. The median radiation dose was 60 Gy (range 48-64 Gy) administered in four fractions every alternate day.

View Article and Find Full Text PDF

Unveiling the role of ACTL6A in uveal melanoma metastasis and immune microenvironment.

Int Immunopharmacol

January 2025

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou 510060, China; Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China. Electronic address:

Purpose: To predict and evaluate the possible mechanisms and clinical value of ACTL6A in the prognosis and development of UM.

Methods: Bioinformatics analyze the relationship between ACTL6A and immunity in UM, which derived from TCGA, Gene Expression Omnibus (GEO) databases. Tumor-infltrated immune cells were demonstrated using QUANTISEQ and MCP-counter.

View Article and Find Full Text PDF

Uveal melanoma (UM) has emerged as one of the most common primary intraocular malignant tumors worldwide. Long non-coding RNAs (lncRNAs) are increasingly recognized as decisive factors in the progression and metastasis of UM, involving in epithelial-mesenchymal transition (EMT) of UM. We conducted a comprehensive analysis of lncRNAs closely associated with EMT-related genes in the TCGA UM cohort, identifying 961 EMT-related lncRNAs.

View Article and Find Full Text PDF

Global incidence and prevalence in uveal melanoma.

Adv Ophthalmol Pract Res

October 2024

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Purpose: The most common intraocular cancer in adults is uveal melanoma (UM). This study aimed to investigate and report the incidence and prognosis of UM in different regions of the world.

Methods: We retrieved relevant data on UM from the PubMed database and analyzed its global incidence and prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!